Erkang Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erkang Yi has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Pixin Ran
State Key Laboratory of Respiratory Diseases National Clinical Research Center for Respiratory Diseases Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China
4 shared publications Yu Liu
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health the First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China
4 shared publicationsChengshu Xie
Guangzhou National Laboratory Guangzhou Guangdong China
3 shared publicationsWeitao Cao
State Key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Medical University Guangzhou Guangdong China
3 shared publicationsXiaoyu Wang
State Key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Medical University Guangzhou Guangdong China
3 shared publicationsXinyue Mei
State Key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Medical University Guangzhou Guangdong China
3 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Routine Serum Albumin and Lipids Identify a Systemic High-Risk COPD Phenotype: A Multi-Omics–Derived, Clinically Actionable Framework
Background: COPD risk stratification still centers on airflow limitation, yet patients with comparable spirometric stages frequently diverge in disease progression, multimorbidity, and survival. A clinically feasible laboratory panel that captures this systemic risk is urgently needed but lacking. We aimed to derive a translatable, routine-laboratory-based biomarker signature that prospectively identifies systemic high-risk COPD by integrating population multi-omics with longitudinal outcomes.Methods: We integrated genome-wide variants, Olink plasma proteomics, and Nightingale NMR metabolomics from 43,551 UK Biobank participants using Multi-Omics Factor Analysis. Multi-omics signals associated with COPD burden, lung-function decline, and mortality were translated into a routine laboratory clustering framework based on serum albumin, total cholesterol, and LDL cholesterol. The signature was evaluated in UK Biobank and externally validated in the Early Chronic Obstructive Pulmonary Disease cohort (ECOPD; n=2,029). Genetic, network, and exploratory Tie-COPD post-hoc analyses assessed biological and translational relevance.Findings: Multi-omics integration identified molecular programs converging on lipid remodeling, cholesterol handling, inflammation, and albumin-related biology. The three-marker framework defined five clinically ordered clusters. C5 represented a systemic high-risk subgroup with greater COPD burden, impaired lung function, multisystem comorbidity, and higher 14-year mortality beyond GOLD staging. ECOPD validation reproduced this gradient, with C5 showing poorer lung function, adverse CT emphysema features, faster lung-function decline, higher exacerbation burden, and increased COPD progression risk. Genetic and network analyses prioritized APOE/lipid and SERPINA1/albumin-protease cascades converging on C5. Tie-COPD analysis suggested limited symptomatic benefit from tiotropium in a C5-like low-albumin profile.Interpretation: A simple albumin-lipid signature identifies a systemic high-risk COPD phenotype characterized by inflammation, altered lipid metabolism, reduced albumin reserve, adverse respiratory outcomes, and potential therapeutic relevance. This framework may support risk stratification beyond spirometry and future precision trial design.
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRoutine Serum Albumin and Lipids Identify a Systemic High-Risk COPD Phenotype: A Multi-Omics–Derived, Clinically Actionable Framework
Background: COPD risk stratification still centers on airflow limitation, yet patients with comparable spirometric stages frequently diverge in disease progression, multimorbidity, and survival. A clinically feasible laboratory panel that captures this systemic risk is urgently needed but lacking. We aimed to derive a translatable, routine-laboratory-based biomarker signature that prospectively identifies systemic high-risk COPD by integrating population multi-omics with longitudinal outcomes.Methods: We integrated genome-wide variants, Olink plasma proteomics, and Nightingale NMR metabolomics from 43,551 UK Biobank participants using Multi-Omics Factor Analysis. Multi-omics signals associated with COPD burden, lung-function decline, and mortality were translated into a routine laboratory clustering framework based on serum albumin, total cholesterol, and LDL cholesterol. The signature was evaluated in UK Biobank and externally validated in the Early Chronic Obstructive Pulmonary Disease cohort (ECOPD; n=2,029). Genetic, network, and exploratory Tie-COPD post-hoc analyses assessed biological and translational relevance.Findings: Multi-omics integration identified molecular programs converging on lipid remodeling, cholesterol handling, inflammation, and albumin-related biology. The three-marker framework defined five clinically ordered clusters. C5 represented a systemic high-risk subgroup with greater COPD burden, impaired lung function, multisystem comorbidity, and higher 14-year mortality beyond GOLD staging. ECOPD validation reproduced this gradient, with C5 showing poorer lung function, adverse CT emphysema features, faster lung-function decline, higher exacerbation burden, and increased COPD progression risk. Genetic and network analyses prioritized APOE/lipid and SERPINA1/albumin-protease cascades converging on C5. Tie-COPD analysis suggested limited symptomatic benefit from tiotropium in a C5-like low-albumin profile.Interpretation: A simple albumin-lipid signature identifies a systemic high-risk COPD phenotype characterized by inflammation, altered lipid metabolism, reduced albumin reserve, adverse respiratory outcomes, and potential therapeutic relevance. This framework may support risk stratification beyond spirometry and future precision trial design.
- Open Access
Integrative GWAS and Mendelian Randomization Analysis Identifies IREB2 and CD27+ Memory B Cells as Core Drivers of COPD to Lung Cancer Progression
Chronic obstructive pulmonary disease (COPD) associates with increased lung cancer incidence and shares genetic susceptibility, yet its independent causal role and driver mechanisms are poorly understood. We integrated data from the National Health and Nutrition Examination Survey (NHANES) cohort with genome‐wide association studies (GWAS) summary statistics and Mendelian randomization analyses to map genetic correlations and infer causality between COPD phenotypes and lung cancer. Post‐GWAS methods—including transcriptome‐wide association study, colocalization, partitioned heritability via heritability estimation from summary statistics (ρ‐HESS), and cross‐phenotype association (CPASSOC)—identified shared susceptibility loci, highlighting IREB2 and CD27⁺ B cells as potential mediators. Elevated IREB2 expression correlated with accelerated lung‐function decline in COPD but predicted improved prognosis in lung cancer B cells, whereas higher CD27⁺ B cell levels in COPD were associated with protumorigenic activity. Single‐cell transcriptomic analysis and in vitro knockdown experiments confirmed IREB2's role in modulating B‐cell activation and apoptosis pathways within tumors. These results support COPD as an independent lung cancer risk factor and implicate IREB2 and CD27⁺ B cells in COPD‐to‐cancer progression, laying groundwork for early detection and targeted intervention in high‐risk individuals.
Open AccessIntegrative GWAS and Mendelian Randomization Analysis Identifies IREB2 and CD27+ Memory B Cells as Core Drivers of COPD to Lung Cancer Progression
Chronic obstructive pulmonary disease (COPD) associates with increased lung cancer incidence and shares genetic susceptibility, yet its independent causal role and driver mechanisms are poorly understood. We integrated data from the National Health and Nutrition Examination Survey (NHANES) cohort with genome‐wide association studies (GWAS) summary statistics and Mendelian randomization analyses to map genetic correlations and infer causality between COPD phenotypes and lung cancer. Post‐GWAS methods—including transcriptome‐wide association study, colocalization, partitioned heritability via heritability estimation from summary statistics (ρ‐HESS), and cross‐phenotype association (CPASSOC)—identified shared susceptibility loci, highlighting IREB2 and CD27⁺ B cells as potential mediators. Elevated IREB2 expression correlated with accelerated lung‐function decline in COPD but predicted improved prognosis in lung cancer B cells, whereas higher CD27⁺ B cell levels in COPD were associated with protumorigenic activity. Single‐cell transcriptomic analysis and in vitro knockdown experiments confirmed IREB2's role in modulating B‐cell activation and apoptosis pathways within tumors. These results support COPD as an independent lung cancer risk factor and implicate IREB2 and CD27⁺ B cells in COPD‐to‐cancer progression, laying groundwork for early detection and targeted intervention in high‐risk individuals.
- Open Access
Long Noncoding RNA Interleukin 6 Antisense RNA 1 Promotes Inflammatory Effects in Lung Macrophages via Exosomes Through the S100A9/TLR4 Pathway in Chronic Obstructive Pulmonary Disease Progression
This study investigates the role of interleukin 6 antisense RNA 1 (IL6‐AS1), a highly expressed long noncoding RNA (lncRNA), in chronic obstructive pulmonary disease (COPD). An adeno‐associated virus (AAV) was used to induce the expression of IL6‐AS1 in mice, and they were exposed to cigarette smoke to establish a COPD model. IL6‐AS1‐overexpressing mice exposed to cigarette smoke demonstrated exacerbated COPD‐like pathologies. Integrated with single‐cell RNA sequencing analysis of COPD patients and pulmonary fibroblast–macrophage coculture system, our findings indicate that the upregulation of IL6‐AS1 in fibroblasts enhances the interaction between the S100A9 protein and the AGER and TLR4 receptors on lung macrophages, thereby exacerbating pulmonary inflammation. The molecular mechanism likely involves exosome‐mediated secretion, with IL6‐AS1 binding to S100A9 protein. These findings suggest that IL6‐AS1 may facilitate crosstalk between fibroblasts and macrophages, contributing to increased pulmonary inflammation, an effect that can be blocked by paquinimod. Mendelian randomization analysis further suggests a potential shared causal variant between IL6‐AS1 and COPD risk. Taken together, this investigation provides valuable insights into the function of IL6‐AS1 and its potential implications for the pathogenesis and therapeutic strategies in COPD.
Open AccessLong Noncoding RNA Interleukin 6 Antisense RNA 1 Promotes Inflammatory Effects in Lung Macrophages via Exosomes Through the S100A9/TLR4 Pathway in Chronic Obstructive Pulmonary Disease Progression
This study investigates the role of interleukin 6 antisense RNA 1 (IL6‐AS1), a highly expressed long noncoding RNA (lncRNA), in chronic obstructive pulmonary disease (COPD). An adeno‐associated virus (AAV) was used to induce the expression of IL6‐AS1 in mice, and they were exposed to cigarette smoke to establish a COPD model. IL6‐AS1‐overexpressing mice exposed to cigarette smoke demonstrated exacerbated COPD‐like pathologies. Integrated with single‐cell RNA sequencing analysis of COPD patients and pulmonary fibroblast–macrophage coculture system, our findings indicate that the upregulation of IL6‐AS1 in fibroblasts enhances the interaction between the S100A9 protein and the AGER and TLR4 receptors on lung macrophages, thereby exacerbating pulmonary inflammation. The molecular mechanism likely involves exosome‐mediated secretion, with IL6‐AS1 binding to S100A9 protein. These findings suggest that IL6‐AS1 may facilitate crosstalk between fibroblasts and macrophages, contributing to increased pulmonary inflammation, an effect that can be blocked by paquinimod. Mendelian randomization analysis further suggests a potential shared causal variant between IL6‐AS1 and COPD risk. Taken together, this investigation provides valuable insights into the function of IL6‐AS1 and its potential implications for the pathogenesis and therapeutic strategies in COPD.
- 13 May 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 494, 138569
Biomass fuel induces neuroinflammation and neurodegeneration via the astrocyte-microglia IL-17A/IL-17RA pathway
- 13 May 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 494, 138569
Biomass fuel induces neuroinflammation and neurodegeneration via the astrocyte-microglia IL-17A/IL-17RA pathway
- Open Access
- 4 August 2024
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 81 (1) , 1-24
The influence of CLEC5A on early macrophage-mediated inflammation in COPD progression
Chronic obstructive pulmonary disease (COPD) is a complex syndrome with poorly understood mechanisms driving its early progression (GOLD stages 1–2). Elucidating the genetic factors that influence early-stage COPD, particularly those related to airway inflammation and remodeling, is crucial. This study analyzed lung tissue sequencing data from patients with early-stage COPD (GSE47460) and smoke-exposed mice. We employed Weighted Gene Co-Expression Network Analysis (WGCNA) and machine learning to identify potentially pathogenic genes. Further analyses included single-cell sequencing from both mice and COPD patients to pinpoint gene expression in specific cell types. Cell–cell communication and pseudotemporal analyses were conducted, with findings validated in smoke-exposed mice. Additionally, Mendelian randomization (MR) was used to confirm the association between candidate genes and lung function/COPD. Finally, functional validation was performed in vitro using cell cultures. Machine learning analysis of 30 differentially expressed genes identified 8 key genes, with CLEC5A emerging as a potential pathogenic factor in early-stage COPD. Bioinformatics analyses suggested a role for CLEC5A in macrophage-mediated inflammation during COPD. Two-sample Mendelian randomization linked CLEC5A single nucleotide polymorphisms (SNPs) with Forced Expiratory Volume in One Second (FEV1), FEV1/Forced Vital Capacity (FVC) and early/later on COPD. In vitro, the knockdown of CLEC5A led to a reduction in inflammatory markers within macrophages. Our study identifies CLEC5A as a critical gene in early-stage COPD, contributing to its pathogenesis through pro-inflammatory mechanisms. This discovery offers valuable insights for developing early diagnosis and treatment strategies for COPD and highlights CLEC5A as a promising target for further investigation.
- 4 August 2024
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 81 (1) , 1-24
Open AccessThe influence of CLEC5A on early macrophage-mediated inflammation in COPD progression
Chronic obstructive pulmonary disease (COPD) is a complex syndrome with poorly understood mechanisms driving its early progression (GOLD stages 1–2). Elucidating the genetic factors that influence early-stage COPD, particularly those related to airway inflammation and remodeling, is crucial. This study analyzed lung tissue sequencing data from patients with early-stage COPD (GSE47460) and smoke-exposed mice. We employed Weighted Gene Co-Expression Network Analysis (WGCNA) and machine learning to identify potentially pathogenic genes. Further analyses included single-cell sequencing from both mice and COPD patients to pinpoint gene expression in specific cell types. Cell–cell communication and pseudotemporal analyses were conducted, with findings validated in smoke-exposed mice. Additionally, Mendelian randomization (MR) was used to confirm the association between candidate genes and lung function/COPD. Finally, functional validation was performed in vitro using cell cultures. Machine learning analysis of 30 differentially expressed genes identified 8 key genes, with CLEC5A emerging as a potential pathogenic factor in early-stage COPD. Bioinformatics analyses suggested a role for CLEC5A in macrophage-mediated inflammation during COPD. Two-sample Mendelian randomization linked CLEC5A single nucleotide polymorphisms (SNPs) with Forced Expiratory Volume in One Second (FEV1), FEV1/Forced Vital Capacity (FVC) and early/later on COPD. In vitro, the knockdown of CLEC5A led to a reduction in inflammatory markers within macrophages. Our study identifies CLEC5A as a critical gene in early-stage COPD, contributing to its pathogenesis through pro-inflammatory mechanisms. This discovery offers valuable insights for developing early diagnosis and treatment strategies for COPD and highlights CLEC5A as a promising target for further investigation.
- Open Access
- 14 June 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (6) , e1292
Smad3‐mediated lncRNA HSALR1 enhances the non‐classic signalling pathway of TGF‐β1 in human bronchial fibroblasts by binding to HSP90AB1
Background: Chronic obstructive pulmonary disease (COPD) is one of the diseases with high mortality and morbidity with complex pathogenesis. Airway remodeling is an unavoidable pathological characteristic. However, the molecular mechanisms of airway remodeling are incompletely defined.Methods: lncRNAs highly correlated with transforming growth factor beta 1(TGF–β1) expression were chosen, the lncRNA ENST00000440406 (named HSP90AB1 Assoicated LncRNA 1, HSALR1) was chosen for further functional experiments. Dual luciferase and ChIP assay were used to detect the upstream of HSALR1, transcriptome sequencing, Cck–8, Edu, cell proliferation, cell cycle assay, and WB detection of pathway levels confirmed the effect of HSALR1 on fibroblast proliferation and phosphorylation levels of related pathways. Mice was infected with adeno–associated virus (AAV) to express HSALR1 by intratracheal instillation under anesthesia and was exposure to cigarette smoke, then mouse lung function was performed and the pathological sections of lung tissues were analyzed.Results: Herein, lncRNA HSALR1 was identified as highly correlated with the TGF–β1 and mainly expressed in human lung fibroblasts. HSALR1 was induced by Smad3 and promoted fibroblasts proliferation. Mechanistically, it could directly bind to HSP90AB1 protein, and acted as a scaffold to stabilize the binding between Akt and HSP90AB1 to promote Akt phosphorylation. In vivo, mice expressed HSALR1 by AAV was exposure to cigarette smoke (CS) for COPD modeling. We found that lung function was worse and airway remodeling was more pronounced in HSLAR1 mice compare to wild type (WT) mice.Conclusion: Our results suggest that lncRNA HSALR1 binds to HSP90AB1 and Akt complex component, and enhances activity of the TGF–β1 smad3–independent pathway. This finding described here suggest that lncRNA can participate in COPD development, and HSLAR1 is a promising molecular target of COPD therapy.
- 14 June 2023
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (6) , e1292
Open AccessSmad3‐mediated lncRNA HSALR1 enhances the non‐classic signalling pathway of TGF‐β1 in human bronchial fibroblasts by binding to HSP90AB1
Background: Chronic obstructive pulmonary disease (COPD) is one of the diseases with high mortality and morbidity with complex pathogenesis. Airway remodeling is an unavoidable pathological characteristic. However, the molecular mechanisms of airway remodeling are incompletely defined.Methods: lncRNAs highly correlated with transforming growth factor beta 1(TGF–β1) expression were chosen, the lncRNA ENST00000440406 (named HSP90AB1 Assoicated LncRNA 1, HSALR1) was chosen for further functional experiments. Dual luciferase and ChIP assay were used to detect the upstream of HSALR1, transcriptome sequencing, Cck–8, Edu, cell proliferation, cell cycle assay, and WB detection of pathway levels confirmed the effect of HSALR1 on fibroblast proliferation and phosphorylation levels of related pathways. Mice was infected with adeno–associated virus (AAV) to express HSALR1 by intratracheal instillation under anesthesia and was exposure to cigarette smoke, then mouse lung function was performed and the pathological sections of lung tissues were analyzed.Results: Herein, lncRNA HSALR1 was identified as highly correlated with the TGF–β1 and mainly expressed in human lung fibroblasts. HSALR1 was induced by Smad3 and promoted fibroblasts proliferation. Mechanistically, it could directly bind to HSP90AB1 protein, and acted as a scaffold to stabilize the binding between Akt and HSP90AB1 to promote Akt phosphorylation. In vivo, mice expressed HSALR1 by AAV was exposure to cigarette smoke (CS) for COPD modeling. We found that lung function was worse and airway remodeling was more pronounced in HSLAR1 mice compare to wild type (WT) mice.Conclusion: Our results suggest that lncRNA HSALR1 binds to HSP90AB1 and Akt complex component, and enhances activity of the TGF–β1 smad3–independent pathway. This finding described here suggest that lncRNA can participate in COPD development, and HSLAR1 is a promising molecular target of COPD therapy.
- Open Access
- 19 July 2021
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (7) , e479
Long noncoding RNA IL6‐AS1 is highly expressed in chronic obstructive pulmonary disease and is associated with interleukin 6 by targeting miR‐149‐5p and early B‐cell factor 1
Chronic obstructive pulmonary disease is a complex condition with multiple etiologies, including inflammation. We identified a novel long noncoding RNA (lncRNA), interleukin 6 antisense RNA 1 (IL6‐AS1), which is upregulated in this disease and is associated with airway inflammation. We found that IL6‐AS1 promotes the expression of inflammatory factors, especially interleukin (IL) 6. Mechanistically, cytoplasmic IL6‐AS1 acts as an endogenous sponge by competitively binding to the microRNA miR‐149‐5p to stabilize IL‐6 mRNA. Nuclear IL6‐AS1 promotes IL‐6 transcription by recruiting early B‐cell factor 1 to the IL‐6 promoter, which increases the methylation of the H3K4 histone and acetylation of the H3K27 histone. We propose a model of lncRNA expression in both the nucleus and cytoplasm that exerts similar effects through differing mechanisms, and IL6‐AS1 probably increases inflammation via multiple pathways.
- 19 July 2021
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (7) , e479
Open AccessLong noncoding RNA IL6‐AS1 is highly expressed in chronic obstructive pulmonary disease and is associated with interleukin 6 by targeting miR‐149‐5p and early B‐cell factor 1
Chronic obstructive pulmonary disease is a complex condition with multiple etiologies, including inflammation. We identified a novel long noncoding RNA (lncRNA), interleukin 6 antisense RNA 1 (IL6‐AS1), which is upregulated in this disease and is associated with airway inflammation. We found that IL6‐AS1 promotes the expression of inflammatory factors, especially interleukin (IL) 6. Mechanistically, cytoplasmic IL6‐AS1 acts as an endogenous sponge by competitively binding to the microRNA miR‐149‐5p to stabilize IL‐6 mRNA. Nuclear IL6‐AS1 promotes IL‐6 transcription by recruiting early B‐cell factor 1 to the IL‐6 promoter, which increases the methylation of the H3K4 histone and acetylation of the H3K27 histone. We propose a model of lncRNA expression in both the nucleus and cytoplasm that exerts similar effects through differing mechanisms, and IL6‐AS1 probably increases inflammation via multiple pathways.